AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer

Gynecologic Oncology

Volumn 135, Issue 2, 2014, Pages 325-332

  Xie, Yi ^a   Hicks, Martin J ^a   Kaminsky, Stephen M ^a   Moore, Malcolm A S ^b   Crystal, Ronald G ^a   Rafii, Arash ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

AAV vector; Anti angiogenesis; Bevacizumab; Gene therapy; Ovarian cancer

Indexed keywords

ADENOVIRUS VECTOR RHESUS SEROTYPE 10 BEVACIZUMAB MONOCLONAL ANTIBODY; ANTINEOPLASTIC AGENT; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CARCINOMATOSIS; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; GENETIC CODE; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM TUMOR; SINGLE DRUG DOSE; SURVIVAL RATE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA; CELL PROLIFERATION; DEPENDOPARVOVIRUS; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84913613950     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.07.105     Document Type: Article

References (35)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. D. Jelovac, and D.K. Armstrong Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J Clin 61 2011 183 203
3. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200
4. M. Markman New developments in the anti-neoplastic drug management of ovarian cancer F1000Prime Rep 5 2013 48
5. S.M. Weis, and D.A. Cheresh Tumor angiogenesis: molecular pathways and therapeutic targets Nat Med 17 2011 1359 1370
6. L. Yu, L. Deng, J. Li, Y. Zhang, and L. Hu The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis Gynecol Oncol 128 2013 391 396
7. L.G. Presta, H. Chen, S.J. O'Connor, V. Chisholm, Y.G. Meng, and L. Krummen Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
8. S. Mabuchi, Y. Terai, K. Morishige, A. Tanabe-Kimura, H. Sasaki, and M. Kanemura Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model Clin Cancer Res 14 2008 7781 7789
9. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study J Clin Oncol 25 2007 5165 5171
10. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
11. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, and H. Huang Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 2011 2473 2483
12. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, and A. Husain OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
13. E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, and G. Kristensen Aurelia: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 30 2012 [18-suppl].
14. A. Du Bois, A. Floquet, J.W. Kim, J. Rau, J.M. Del Campo, and M. Friedlander Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international intergroup trial (AGO-OVAR16) J Clin Oncol 31 2013 [18-suppl]
15. T.J. Herzog, G. Scambia, B.G. Kim, C. Lhomme, J. Markowska, and I. Ray-COquard A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma Gynecol Oncol 130 2013 25 30
16. K.H. Baumann, A. du Bois, W. Meier, J. Rau, P. Wimberger, and J. Sehouli A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy Ann Oncol 23 2012 2265 2271
17. W.P. Tew, N. Colombo, I. Ray-COquard, J.M. Del Campo, A. Oza, and D. Pereira Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2 2013 Parallel-Arm Study Cancer
18. D. Lambrechts, H.J. Lenz, Carmeliet P. de HS, and S.J. Scherer Markers of response for the antiangiogenic agent bevacizumab J Clin Oncol 31 2013 1219 1230
19. B.J. Monk, E. Pujade-Lauraine, and R.A. Burger Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease Ann Oncol 24 Suppl. 10 2013 x53 x58
20. M. Watanabe, J.L. Boyer, and R.G. Crystal AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors Gene Ther 17 2010 1042 1051
21. Y. Mao, S. Kiss, J.L. Boyer, N.R. Hackett, J. Qiu, and A. Carbone Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab Hum Gene Ther 22 2011 1525 1535
22. J.P. Delord, C. Allal, M. Canal, E. Mery, P. Rochaix, and I. Hennebelle Selective inhibition of HER2 inhibits AKT signal transduction and prolongs disease-free survival in a micrometastasis model of ovarian carcinoma Ann Oncol 16 2005 1889 1897
23. V. Vassileva, C.J. Allen, and M. Piquette-Miller Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer Mol Cancer Ther 7 2008 630 637
24. A. Rafii, P. Mirshahi, M. Poupot, A.M. Faussat, A. Simon, and E. Ducros Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours PLoS One 3 2008 e3894
25. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
26. J. Pasquier, B.S. Guerrouahen, T.H. Al, P. Ghiabi, M. Maleki, and N. bu-Kaoud Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance J Transl Med 11 2013 94
27. J.F. Lu, R. Bruno, S. Eppler, W. Novotny, B. Lum, and J. Gaudreault Clinical pharmacokinetics of bevacizumab in patients with solid tumors Cancer Chemother Pharmacol 62 2008 779 786
28. M. Hampl, T. Tanaka, P.S. Albert, J. Lee, N. Ferrari, and H.A. Fine Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites Hum Gene Ther 12 2001 1713 1729
29. R. Calcedo, and J.M. Wilson Humoral immune response to AAV Front Immunol 4 2013 341
30. I.V. Subramanian, T.M. Bui Nguyen, A.M. Truskinovsky, J. Tolar, B.R. Blazar, and S. Ramakrishnan Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival Cancer Res 66 2006 4319 4328
31. L.H. Vandenberghe, E. Breous, H.J. Nam, G. Gao, R. Xiao, and A. Sandhu Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints Gene Ther 16 2009 1416 1428
32. M.J. Chiuchiolo, S.M. Kaminsky, D. Sondhi, N.R. Hackett, J.B. Rosenberg, and E.Z. Frenk Intrapleural administration of an AAVrh.10 vector coding for human alpha1-antitrypsin for the treatment of alpha1-antitrypsin deficiency Hum Gene Ther Clin Dev 24 2013 161 173
33. M. Castells, D. Milhas, C. Gandy, B. Thibault, A. Rafii, and J.P. Delord Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation Cell Death Dis 4 2013 e887
34. M. Singh, S.S. Couto, W.F. Forrest, A. Lima, J.H. Cheng, and R. Molina Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models J Pathol 227 2012 417 430
35. L.M. Randall, and B.J. Monk Bevacizumab toxicities and their management in ovarian cancer Gynecol Oncol 117 2010 497 504